CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Changes in Registrant’s Certifying Accountant

CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01

(d) Exhibits.

16.1 Letter of BDO USA, LLP dated June 24, 2019


CYTRX CORP Exhibit

To view the full exhibit click here

Story continues below

About CYTRX CORPORATION (NASDAQ:CYTR)

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

An ad to help with our costs